Safety Considerations in the Use of Botulinum Toxins in Children With Cerebral Palsy

PM and R

Volumn 2, Issue 4, 2010, Pages 282-284

  Apkon, Susan D ^a   Cassidy, Danielle ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; NEUTRALIZING ANTIBODY;

ARTICLE; CARDIOPULMONARY INSUFFICIENCY; CEREBRAL PALSY; CHILD; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERANCE; DYSPHAGIA; FOOD AND DRUG ADMINISTRATION; HEART ARRHYTHMIA; HUMAN; INJECTION; NERVE ENDING; NEUROMUSCULAR SYNAPSE; PNEUMONIA; PRIORITY JOURNAL; SEIZURE; STROKE; WEAKNESS;

ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; CEREBRAL PALSY; CHILD; HUMANS; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS;

EID: 77951960727     PISSN: 19341482     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pmrj.2010.02.006     Document Type: Article

References (24)

1. Early Communication about an Ongoing Safety Review of Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B) (2008). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPa tientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070 366.htm Accessed February 23, 2010
2. Dolly J.O. Therapeutic and research exploitation of botulinum neurotoxins. Eur J Neurol 4 (1997) S5-S10
3. Yablon S.A., Brashear A., Gordon M.F., et al. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: A pooled-data analysis of three clinical trials. Clin Ther 29 (2007) 683-690
4. Product Information: BOTOX (onobotulinumtoxinA) (2009), Allergan Pharmaceuticals, Irvine, CA
5. Delgado MR, Hirtz D, Aisen M, et al. Practice parameter: Pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology;74:336-343.
6. Ade-Hall R.A., and Moore A.P. Botulinum toxin type A in the treatment of lower limb spasticity in cerebral palsy. Cochrane Database Syst Rev (2000) CD001408
7. Bjornson K., Hays R., Graubert C., et al. Botulinum toxin for spasticity in children with cerebral palsy: A comprehensive evaluation. Pediatrics 120 (2007) 49-58
8. Criswell S.R., Crowner B.E., and Racette B.A. The use of botulinum toxin therapy for lower-extremity spasticity in children with cerebral palsy. Neurosurg Focus 21 (2006) e1
9. Koman L.A., Mooney III J.F., Smith B.P., Walker F., and Leon J.M. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: A randomized, double-blind, placebo-controlled trial. BOTOX Study Group. J Pediatr Orthop 20 (2000) 108-115
10. Lukban M.B., Rosales R.L., and Dressler D. Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: A summary of evidence. J Neural Transm 116 (2009) 319-331
11. Sutherland D.H., Kaufman K.R., Wyatt M.P., Chambers H.G., and Mubarak S.J. Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait Posture 10 (1999) 1-9
12. Wasiak J., Hoare B., and Wallen M. Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy. Cochrane Database Syst Rev (2004) CD003469
13. Graham H.K., Aoki K.R., Autti-Ramo I., et al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture 11 (2000) 67-79
14. Kinnett D. Botulinum toxin A injections in children: Technique and dosing issues. Am J Phys Med Rehabil 83 (2004) S59-S64
15. Public Citizen. Petition to the FDA requesting regulatory action concerning the possible spread of botulinum toxin (Botox, Myobloc) from the site of injection to other parts of the body (HRG Publication #1834) (2008). http://www.citizen.org/publications/release.cfm?ID=7559 Accessed February 23, 2010
16. Albavera-Hernandez C., Rodriguez J.M., and Idrovo A.J. Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials. Clin Rehabil 23 (2009) 394-407
17. Crowner B.E., and Racette B.A. Prospective study examining remote effects of botulinum toxin a in children with cerebral palsy. Pediatr Neurol 39 (2008) 253-258
18. Willis A.W., Crowner B., Brunstrom J.E., Kissel A., and Racette B.A. High dose botulinum toxin A for the treatment of lower extremity hypertonicity in children with cerebral palsy. Dev Med Child Neurol 49 (2007) 818-822
19. Crowner B.E., Brunstrom J.E., and Racette B.A. Iatrogenic botulism due to therapeutic botulinum toxin a injection in a pediatric patient. Clin Neuropharmacol 30 (2007) 310-313
20. Howell K., Selber P., Graham H.K., and Reddihough D. Botulinum neurotoxin A: An unusual systemic effect. J Paediatr Child Health 43 (2007) 499-501
21. Partikian A., and Mitchell W.G. Iatrogenic botulism in a child with spastic quadriparesis. J Child Neurol 22 (2007) 1235-1237
22. Kolaski K., Ajizian S.J., Passmore L., Pasutharnchat N., Koman L.A., and Smith B.P. Safety profile of multilevel chemical denervation procedures using phenol or botulinum toxin or both in a pediatric population. Am J Phys Med Rehabil 87 (2008) 556-566
23. Food and Drug Administration. Follow-up to the February 8, 2008, Early Communication about an Ongoing Safety Review of Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B). FDA response to petition (2009). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPa tientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm143 819.htm
24. Bazzano A.T., Mangione-Smith R., Schonlau M., Suttorp M.J., and Brook R.H. Off-label prescribing to children in the United States outpatient setting. Acad Pediatr 9 (2009) 81-88